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OBJECTIVES We compared the risk of stent thrombosis (ST) after drug-eluting stents (DES) versus
bare-metal stents (BMS), and tested the hypothesis that the risk of DES thrombosis is related
to stent length.
BACKGROUND Whether DES increase the risk of ST remains unclear. Given the very low restenosis rate after
drug-eluting stenting, longer stents are frequently implanted for the same lesion length in
comparison to BMS.
METHODS We included in a meta-analysis 10 randomized studies comparing DES and BMS. Overall,
5,030 patients were included (2,602 were allocated to DES and 2,428 to BMS). The risk of
thrombosis after DES versus BMS was compared, and the relationship between the rate of
DES thrombosis and stent length was evaluated.
RESULTS Incidence of ST was not increased in patients receiving DES (0.58% vs. 0.54% for BMS; odds
ratio: 1.05; 95% confidence interval [CI]: 0.51 to 2.15; p 1.000). The overall rate of ST did
not differ significantly between patients receiving sirolimus- or paclitaxel-eluting stents
(0.57% vs. 0.58%; p 1.000). We found a significant relation between the rate of ST and the
stented length (Y  1.455  0.121 X; 95% CI for beta: 0.014 to 0.227; R  0.716; p 
0.031). In patients with DES, mean stented length was longer in those suffering ST (23.4 
8.1 mm vs. 21.3  4.1 mm, p  0.025).
CONCLUSIONS Drug-eluting stents do not increase the risk of ST, at least under appropriate anti-platelet
therapy. The risk of ST after DES implantation is related to stent length. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.065Cardiol 2005;45:954–9) © 2005 by the American College of Cardiology Foundation
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srug-eluting stents (DES) have dramatically reduced reste-
osis in comparison with bare-metal stents (BMS) (1–11).
ome initial reports warned of a possible increase in the risk
f stent thrombosis (ST). However, whether ST is increased
ith the use of DES as compared with BMS has not been
emonstrated, at least under appropriate antiplatelet therapy
1–11).
Given the very low restenosis rate after DES implanta-
ion, longer stents have frequently been implanted, as-
uming that optimizing immediate angiographic results as
ossible—even covering nonsignificant coronary lesions—
s followed by better clinical outcomes. Some studies have
hown that ST after BMS implantation is related to
he stent length, rather than lesion length (12). We hy-
othesized that stented length may be related to the
isk of ST and also to the use of DES. To test this
ypothesis, we performed a meta-analysis of 10 studies that
andomly compared DES and BMS. We also used these
tudies to compare the risk of ST after DES versus BMS
mplantation.
From the Division of Interventional Cardiology, Cardiovascular Institute, Hospital
línico San Carlos, Madrid, Spain. This work was presented in part at the 77th
nnual Scientific Sessions of the American Heart Association, New Orleans,
ouisiana, November 2004.C
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004, accepted November 2, 2004.ATIENTS AND METHODS
tudies included in the analysis. We included 10 ran-
omized studies comparing DES and BMS published
efore June 2004: Randomized study with sirolimus-coated
x VELocity balloon-expandable stent in the treatment of
atients with de novo native coronary artery lesions
RAVEL) (1); SIRolImUS-Eluting balloon-expandable
tent in the treatment of patients with de novo native
oronary artery lesions (SIRIUS) (2); European multicenter
andomized double-blind study of the SIRolImUS-Eluting
alloon-expandable stent in the treatment of patients with
e novo native coronary artery lesions (E-SIRIUS) (3);
anadian multicenter randomized double-blind study of the
IRolImUS-Eluting balloon-expandable stent in the treat-
ent of patients with de novo native coronary artery lesions
C-SIRIUS) (4); Asian Paclitaxel-Eluting Stent Clinical
rial (ASPECT) (5); European evaluation of pacliTaxel-
luting Stent (ELUTES) (6); Treatment of de novo coro-
ary disease using a single pAclitaXel elUting Stent
TAXUS)-I, -II, and -IV (7–9); and RX ACHIEVE
rug-Eluting coronary stent system In the treatment of
atients with de noVo nativE coronaRy lesions (DELIVER)
10).
In the RAVEL, SIRIUS, E-SIRIUS, and C-SIRIUS
rials, patients were randomly assigned either to slow-release
irolimus-DES (140 g/cm2) or BMS (BX Velocity stent,
ordis Corp., Miami Lakes, Florida). In the ASPECT,
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aclitaxel-DES was used (5,6,10). In the ASPECT trial,
76 patients were randomized in a 1:1:1 fashion to either
aclitaxel 1.3 g/mm2, paclitaxel 3.1 g/mm2, or BMS
Supra-G stent, Cook Inc., West Lafayette, Indiana). In
hat study, 37 patients received cilostazol instead of thien-
pyridines in association with aspirin. This subgroup was
xcluded because this regimen is not the currently accepted
ntiplatelet course after coronary stenting. Other patients
ho did not receive any anti-platelet therapy were also
xcluded (5). In the ELUTES trial, patients were assigned
o paclitaxel 0.2, 0.7, 1.4, and 2.7 g/mm2, or BMS (V-Flex
lus coronary stents, Cook Inc.) (6). In the DELIVER
tudy, the ACHIEVE paclitaxel-DES (3.0 g/mm2) and
he Multilink-Penta BMS (Guidant Corp.) were compared
10). A polymeric paclitaxel-DES was evaluated in the
AXUS trials (7–9). In TAXUS-I, a slow-release
aclitaxel-DES (1.0 g/mm2) was compared with BMS
NIR, Boston Scientific Corp., Natick, Massachusetts) (7).
n the TAXUS-II study, a first cohort of patients compared
slow-release paclitaxel-DES with BMS, and a second
ohort evaluated a moderate-release paclitaxel-DES (8).
inally, in TAXUS-IV, the slow-release paclitaxel-DES
as compared with BMS (Express, Boston Scientific Corp.)
9). Overall, 5,030 patients were included: 2,602 allocated to
ES, and 2,428 to BMS.
tenting procedure and antiplatelet therapy. In most
tudies, conventional stent implantation was mandated,
lthough direct stenting was allowed in some trials (3,4).
onversely, most studies allowed post-dilation. In the
tudies in which the implantation of 1 stent was allowed,
tents were overlapped in 28% to 36% of cases (2–4,9). In
ome studies, intravascular ultrasound was used to guide
oronary stenting (5,7,8). In most of them, however, only
ome patients underwent intracoronary ultrasound either by
nclusion in a sub-study or at the operator’s discretion.
Aspirin was given to all patients indefinitely. Addition-
lly, clopidogrel was given for one (5), two (1–4), three
6,10), or six (7–9) months. The duration of clopidogrel
herapy tended to be longer after paclitaxel than sirolimus
4.2  2.1 months vs. 2.0  0.0 months, respectively, p 
.056). Glycoprotein IIb/IIIa inhibitors were used at the
perator’s discretion in most studies (1–4,6,8,9), although
n some of them it was either not used or discouraged (5,7).
tatistical analysis. The review was conducted according
o the Quality of Reports of Meta-Analyses of Randomized
Abbreviations and Acronyms
BMS  bare-metal stents
CI  confidence interval
DES  drug-eluting stent
LST  late stent thrombosis
OR  odds ratio
ST  stent thrombosislinical Trials (QUOROM) recommendations (13). The (eviewer Manager 4.1 (2000 Cochrane Collaboration) and
he SPSS 10.0 (Chicago, Illinois) statistical packages were
sed.
Quantitative variables are expressed as mean  standard
eviation, and discrete variables as percentages. Associations
etween categorical variables were studied by the chi-square
est or the Fisher exact test (in case any expected value is
5). Comparisons between two mean values were evaluated
ith the Student t or the Mann-Whitney tests, as appro-
riate (normally distributed and not normally distributed
ariables, respectively). The odds ratio (OR) for ST and late
tent thrombosis (LST), and their 95% confidence interval
CI) were calculated comparing DES with BMS rates using
aw data for each study and for the pooled population
intention-to-treat basis). The ST was classified as early
nd late (within or after more than one month after
tenting). The fixed-effect model or the Der Simonian and
aird random-effect model (when p  0.05 for Q test for
eterogeneity) were used. The combined effect for the
eterogeneity was calculated by taking the inverse variance
stimated. The effect of each study was weighted for its
umber of patients.
To evaluate associations between two continuous vari-
bles, the curve fit regression analysis was used, weighting
or the number of patients from each study. The estimated
eta-coefficient as well as its 95% CI was also calculated.
e contacted the principal investigator of all trials in which
1 DES ST occurred in order to compare DES ST with
atients not suffering DES ST. Associations were consid-
red statistically significant when p  0.05.
ESULTS
haracteristics of the studies included for analysis.
able 1 provides the number of patients included in each
tudy. Prevalence of diabetes ranged from 14% to 31%. The
se of glycoprotein IIb/IIIa inhibitors ranged from 0% to
4%. Data from quantitative coronary analysis for each
tudy are shown in Table 2.
isk of ST with DES versus BMS. The rate of ST did
ot differ between DES and BMS (0.58% vs. 0.54%,
espectively; OR: 1.05; 95%CI: 0.51 to 2.15; p  1.000)
Fig. 1A). The rate of LST was also similar (0.23% vs.
.25%, respectively; OR: 0.99; 95%CI: 0.35 to 2.84; p 
.000) (Fig. 1B). After excluding non-polymeric paclitaxel
tudies (ASPECT, ELUTES, and DELIVER), the risk of
oth ST (0.65% vs. 0.55%; OR: 1.19; 95%CI: 0.51 to 2.77;
 0.831) and LST (0.27% vs. 0.27%, respectively, for
ES and BMS; OR: 0.99; 95%CI: 0.29 to 3.43; p 1.000)
as not different.
The rate of DES ST ranged from 0% to 2% among
tudies (Table 2), and it did not differ between patients
eceiving sirolimus and paclitaxel (0.57% [5 of 878] vs.
.58% [10 of 1,724], respectively; p  1.000). Of the 15
ES ST cases, 9 (60%) occurred within 30 days, whereas 640%) were LST. The rate of LST did not differ signifi-
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Drug-Eluting Stent Thrombosis March 15, 2005:954–9antly between sirolimus- and paclitaxel-DES (0.11% [1 of
78] vs. 0.29% [5 of 1,724]; p  0.670). Of the five late
aclitaxel-DES ST, two occurred in the TAXUS-II, two in
he TAXUS-IV, and one in the DELIVER trial. The only
ate sirolimus-eluting ST occurred in the SIRIUS trial.
hen comparing sirolimus-DES with polymeric paclitaxel-
ES, no significant differences were found in the rate of ST
0.57% [5 of 878] vs. 0.73% [7 of 959], respectively; p 
.776) and LST (0.11% [1 of 878] vs. 0.42% [4 of 959],
espectively; p  0.377). Non-polymeric and polymeric
aclitaxel-DES showed no significant differences in the rate
f ST (0.39% [3 of 765] vs. 0.73% [7 of 959], p  0.527)
nd LST (0.13% [1 of 765] vs. 0.42% [4 of 959], p 
.390).
elationship between stent length and risk of DES ST.
sing the curve fit regression analysis, the best fit was
btained with linear regression. We found a significant
ssociation between the incidence of ST and stented length
hat remained after weighting by the number of patients
ncluded in each study (Y1.455 0.121 X; 95% CI for
oefficient beta: 0.014 to 0.227; R 0.646; p 0.031) (Fig.
). Among patients allocated to DES, the mean stented
ength was significantly larger in those suffering ST (23.4 
.1 mm vs. 21.3  4.1 mm, p  0.025; difference of 3.1
m, 95% CI for the difference: 1.05 to 5.15 mm).
There was also a significant association between the
able 1. Studies Included in the Pooled Analysis, Including Type
lycoprotein IIb/IIIa Inhibitors and IVUS Guidance Among Th
Study Drug Stent
N
(Total)
AVEL (1) Sirolimus BX Velocity 238
IRIUS (2) Sirolimus BX Velocity 1,058
-SIRIUS (3) Sirolimus BX Velocity 352
-SIRIUS (4) Sirolimus BX Velocity 100
SPECT (5) Paclitaxel Supra-G 138
LUTES (6) Paclitaxel V-Flex Plus 192
AXUS-I (7) Paclitaxel NIR 61
AXUS-II (8) Paclitaxel NIR 536
AXUS-IV (9) Paclitaxel Express 1,314
ELIVER (10) Paclitaxel Multilink Penta 1,041
ES  drug-eluting stent; IVUS  intravascular ultrasound; NA  not available.
able 2. Rate of Thrombosis in Each Study, as Well as Data Fro
n Each Study
Study
DES
Thrombosis
Mean Lesion
Length
(mm)
Mean Stented
Length
(mm)
Stente
Leng
AVEL (1) 0.0% 9.6 18.0
IRIUS (2) 0.4% 14.4 21.5
-SIRIUS (3) 1.1% 14.9 23.0
-SIRIUS (4) 2.0% 14.5 26.2
SPECT (5) 0.0% 11.1 15.0
LUTES (6) 0.7% 10.8 16.0
AXUS-I (7) 0.0% 10.7 15.0
AXUS-II (8) 1.1% 10.40 15.9
AXUS-IV (9) 0.6% 13.40 21.7
AXUS-IV (10) 0.4% 11.7 19.8LD  minimum lumen diameter; RVD  reference vessel diameter; other abbreviationroportion of patients suffering ST and the mean number of
tents placed per patient, which remained significant after
eighting by the number of patients included in each study
Y  1.765  2.080 X; 95% for beta: 0.439 to 3.722; R
0.752; p  0.020). The mean number of stents placed in
atients with DES ST was 1.33  0.62 (vs. 1.11  0.32 in
hose without ST; p  0.190) (difference 0.22; 95%CI:
0.12 to 0.56). A strong correlation was found between
tent length and the number of stents placed (R  0.875, p
0.001).
No significant association was found between the rate of
ES ST and other variables studied (Table 3).
ISCUSSION
ES thrombosis. The overall rate of ST after DES im-
lantation was 0.6%, and did not differ between sirolimus
nd paclitaxel DES. This incidence is comparable to that of
MS (14). Owing to the possibility of delayed endotheli-
lization and enhanced platelet aggregation after DES
mplantation, initial reports warned about the possibility of
igher risk of ST (15,16). However, recent studies have
eported a low incidence of DES thrombosis under pro-
onged therapy with aspirin plus thienopyridines, compara-
le to that of BMS, even in unstable clinical settings (17).
o differences were found between sirolimus and paclitaxel-
ES, Number of Patients, and Percentage of Use of
llocated to DES
N
ES) Follow-Up Diabetes
Glycoprotein
IIb/IIIa IVUS
20 12 months 16% 10% 40%
33 12 months 25% 60% 24%
75 9 months 19% 14% 17%
50 12 months 24% 58% NA
90 6 months 21% 0% 100%
53 12 months 17% 31% NA
31 12 months 23% 0% 100%
66 12 months 14% 16% 100%
62 9 months 31% 58% 23%
22 9 months 31% 64% NA
e Quantitative Coronary Analysis in Patients Allocated to DES
sion
tio
No. of Stents
Per Patient
Mean RVD
(mm)
Mean MLD
Post-Procedure
(mm)
Mean Stenosis
Post-Procedure
1.00 2.60 2.43 11.90%
1.40 2.80 2.67 5.40%
1.50 2.55 2.43 7.70%
1.60 2.65 2.53 6.10%
1.00 2.94 2.84 3.00%
1.07 2.90 2.70 9.60%
1.00 2.99 2.95 13.56%
1.06 2.75 2.53 10.90%
1.08 2.75 2.26 19.10%
1.11 2.85 2.86 2.7%of D
ose A
(D
1
5
1
1
2
6
5m th
d/Le
th Ra
1.88
1.49
1.70
1.8
1.35
1.48
1.40
1.52
1.58
1.69s as in Table 1.
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March 15, 2005:954–9 Drug-Eluting Stent ThrombosisES. However, the duration of thienopyridines treatment
ended to be longer with paclitaxel; thus, a higher throm-
ogenicity of paclitaxel that might have been mitigated by a
onger duration of dual anti-platelet treatment cannot be
uled out.
All study patients were under thienopyridines. The most
triking factor associated with DES thrombosis is absence of
reatment with ticlopidine/clopidogrel. In the ASPECT
rial, the rate of DES thrombosis in patients receiving
ilostazol instead of thienopyridines was 14.8% (4 of 27) (5).
n another study, 30% of patients withdrawing ticlopidine
arly after DES implantation suffered ST (18). Of the 15
ES thrombosis cases, 6 (40%) were LST. This could be
elated to a delayed stent endothelialization (14), late stent
alapposition (8), aneurysm formation, and even a localized
ypersensitivity to the polymer (19). In comparison with
MS, late stent malapposition occurs more frequently after
irolimus-DES (9% in the SIRIUS trial and 21% in the
AVEL trial). However, in the TAXUS-II trial, late stent
igure 1. (A) Comparison between the rate of stent thrombosis in patie
andomized studies and in the pooled population. (B) Comparison betwee
andomized studies and in the pooled population. CI  confidence intervnts allocated to drug-eluting stents (DES) or bare-metal stents (BMS) in the
n the rate of late stent thrombosis in patients allocated to DES or BMS in the
al; OR  odds ratio.alapposition was not more frequent with paclitaxel-DES
(
igure 2. Relation between stent length and the rate of drug-eluting stent
DES) thrombosis in the different studies included in the meta-analysis. CI
confidence interval.
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Drug-Eluting Stent Thrombosis March 15, 2005:954–9han with BMS (8). Thus, these data should encourage us to
rescribe prolonged combined antiplatelet therapy of aspirin
lus thienopyridines, perhaps for at least one year. In the
AXUS-II trial, 2 of the 3 STs occurred between 6 and 12
onths after DES implantation (8).
elationship between stent length and risk of ST. The
isk of DES thrombosis ranged from 0% to 2% among the
rials. This incidence was significantly related to stent
ength. This also occurs with BMS, and has important
mplications, given the potential serious clinical conse-
uences of ST (12). Probably, as stent length increases, it is
ore difficult to ensure that the stent is fully deployed and
n contact with the vessel wall. In the TAXUS-II trial,
esion length was a predictor of late stent malapposition
20). In a very recent study, the total stent length was
ignificantly associated with the risk of intra-procedural ST
fter sirolimus-DES implantation (21). Additionally, total
tented length is also an independent predictor for creatine
inase-MB fraction after DES implantation (22).
When using DES, interventional cardiologists may be
empted to implant stents that are too long. In the
AXUS-IV trial, for example, it was recommended to
mplant a stent 2 to 4 mm longer than the lesion. However,
he stent length was 8.5 mm longer than the lesion (9). This
ttitude is probably based on two arguments: First, one of
he limitations of intra-coronary brachytherapy is edge-
ffect, and the first reports on DES also warned of the
ossibility of edge effect with the use of DES. However,
andomized trials have not shown an edge-effect caused by
ES. Second, given the very low rate of restenosis after
ES, stent length probably has few implications in the
bsolute rate of subsequent restenosis. In view of the herein
emonstrated relationship between stent length and the risk
f DES thrombosis, it could be recommended not to use
verly long DES if it is not necessary.
tudy limitations. This study has some limitations. First,
s with other meta-analyses (23), inclusion criteria may be
ifferent among studies. Second, follow-up was limited to
2 months in most trials. The possibility of very LST after
Table 3. Relationship Between the Proportion
Clinical and Angiographic Characteristics (Lin
Number of Patients Allocated to DES in Each
Variable Regre
% of patients with diabetes Y  0.6
Use of glycoprotein IIb/IIIa Y  0.4
% of IVUS guidance Y  0.5
Lesion length Y  1
Stented length Y  1
Stented/lesion length Y  1
Number of stents per patient Y  1
RVD Y  6.9
MLD post-procedure Y  3.1
% stenosis post-procedure Y  0.7
Duration of clopidogrel therapy Y  0.7
Abbreviations as in Tables 1 and 2.ES implantation necessitates a more extended follow-upf these patients to better understand the problem of DES
hrombosis (19). However, some studies with DES have
xtended the follow-up at two years, with no or very low risk
f additional ST (24,25). Finally, intravascular ultrasound
as not performed in cases suffering DES thrombosis.
herefore, the underlying mechanisms contributing to the
hysiopathology of DES thrombosis were not provided. At
ur center, we have performed a prospective study using
ntracoronary ultrasound in a series of patients suffering ST
fter BMS implantation. Stent under-expansion (75%),
ncomplete apposition (33%), and edge-dissection (17%)
ere frequently found (26). We can hypothesize that these
echanisms are also involved in DES thrombosis.
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